1. Dopolnjena priporočila za obravnavo bolnikov z melanomom kožeMartina Reberšek, Janja Ocvirk, Primož Strojan, Marko Hočevar, Tanja Mesti, Barbara Perić, Katarina Šmuc Berger, Laura Đorđević Betetto, Vesna Zadnik, Olga Blatnik, Boštjan Luzar, Jože Pižem, Nežka Hribernik, Gaber Plavc, Marko Kokalj, Katarina Barbara Karner, Katarina Zevnik, Maja Marolt-Mušič, Nada Rotovnik-Kozjek, Karla Berlec, Maja Ebert Moltara, Jernej Benedik, Nataša Puzić Ravnjak, 2026, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: koža, rak (medicina), zaščitni ukrepi, dejavniki tveganja, klinična diagnostika, stadij, prognoza, histopatologija, kirurško zdravljenje, radioterapija, sistemsko zdravljenje, sledenje pacientov, prehranska podpora, paliativna oskrba, elektronske knjige
Objavljeno v DiRROS: 07.08.2026; Ogledov: 21; Prenosov: 13
 Celotno besedilo (742,12 KB)
Gradivo ima več datotek! Več... |
2. Determination of copper and other trace elements in serum samples from patients with biliary tract cancers : prospective noninterventional nonrandomized clinical study protocolMartina Reberšek, Nežka Hribernik, Katarina Kozlica, Stefan Marković, Katja Uršič Valentinuzzi, Maja Čemažar, Tea Zuliani, Radmila Milačič Ščančar, Janez Ščančar, 2024, izvirni znanstveni članek Povzetek: Background Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage, when the disease is incurable. Currently used tumor biomarkers have limited diagnostic value for BTCs, so there is an urgent need for sensitive and specific biomarkers for their earlier diagnosis. Deregulation of the homeostasis of trace elements is involved in the carcinogenesis of different cancers, including BTCs. The objective of the study is to determine/compare the total concentrations of copper (Cu), zinc (Zn) and iron (Fe) and the proportions of free Cu and Cu bound to ceruloplasmin (Cp) and the isotopic ratio of 65Cu/63Cu in serum samples from healthy volunteers and cancer patients using inductively coupled plasma-mass spectrometry-based methods (ICP-MS).
Ključne besede: trace elements, copper, predictive biomarkers of response
Objavljeno v DiRROS: 26.06.2026; Ogledov: 192; Prenosov: 70
Celotno besedilo (781,24 KB) |
3. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients : a prospective studyNežka Hribernik, Katja Strašek, Daniel T. Huff, Andrej Studen, Katarina Zevnik, Katja Škalič, Robert Jeraj, Martina Reberšek, 2024, izvirni znanstveni članek Ključne besede: immune checkpoint inhibitors, immune-related adverse effects, quantitative imaging biomarkers
Objavljeno v DiRROS: 24.06.2026; Ogledov: 220; Prenosov: 77
Celotno besedilo (1,21 MB) |
4. Clinical impact of trace elements as potential biomarkers for diagnosis and prediction of response to systemic treatment in gastrointestinal cancersMartina Reberšek, Radmila Milačič Ščančar, Janez Ščančar, Nežka Hribernik, 2026, izvirni znanstveni članek Povzetek: Gastrointestinal cancers are among the most common malignancies worldwide and, at advanced stages, remain incurable. Currently used biomarkers, such as tumour markers, have limited diagnostic value for early detection and relapse, highlighting the urgent need for more sensitive and specific markers. Trace elements are involved in numerous physiological and metabolic processes, and deregulation of their homeostasis is implicated in the carcinogenesis of various cancers, including gastrointestinal malignancies. Several basic and preclinical studies have identified the importance of trace elements in key biological processes. Recent clinical studies and retrospective analyses suggest that fluctuations in trace element levels may be associated with the development and progression of many cancers. Thus, quantitative and dynamic determination of serum trace element concentrations during treatment and follow-up represents a promising option for monitoring treatment efficacy and disease prognosis. Conclusions. Trace elements may serve as potential prognostic and predictive biomarkers for diagnosis and response to systemic treatment.
Ključne besede: gastrointestinal cancers, systemic therapy, prognostic and predictive biomarkers, trace elements
Objavljeno v DiRROS: 18.06.2026; Ogledov: 187; Prenosov: 83
Celotno besedilo (460,84 KB) |
5. Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy : Slovenian real-world dataNežka Hribernik, Rozala Arko, Gorana Gašljević, Martina Reberšek, 2026, izvirni znanstveni članek Povzetek: Adjuvant nivolumab has become the new standard of care for patients with oesophageal and gastroesophageal junction cancer (OEC/GEJC) following neoadjuvant chemoradiotherapy (neoCRT) and surgical resection. In Slovenia, this treatment has been in use since January 2022. Here, we report the first Slovenian real-world experience with adjuvant nivolumab. Patients and methods. We conducted a retrospective, observational cohort study of patients with OEC/GEJC who received adjuvant nivolumab after neoCRT and radical resection between January 2022 and December 2023. Data on patient characteristics, treatment completion, disease progression, and immune-related adverse events (irAEs) were collected from medical records and analysed via descriptive statistics. Results. A total of 17 patients were included. The median follow-up was 34.6 months (range 11.2–55.7). The cohort included 14 (82%) males, with a mean age of 59 years. The Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 15 (88%) patients and 1 for 2 (12%) patients. The tumor location was the esophagus in 9 (53%) patients and the gastroesophageal junction in 8 (47%) patients. At diagnosis, 13 (76%) patients were stage III (8th TNM classification). Histology revealed adenocarcinoma (AC) in 12 (71%) patients and squamous cell carcinoma (SCC) in 5 (29%) patients. Only 6 (35%) patients completed one year of adjuvant nivolumab. Treatment was discontinued in 5 (29%) patients due to disease progression and in 6 (35%) patients due to irAEs. Overall, 11 (65%) patients experienced irAEs of any grade. Grade 3 or 4 irAEs occurred in 4 (24%) patients: myocarditis G4 in 1 (6%) patient and colitis G3 in 3 (18%) patients. No irAE-related deaths were reported. The median disease-free survival (DFS) was 21.4 months (95% confidence interval [CI], 14.6–28.9). Conclusions. Real-world data from Slovenia indicate that 65% of patients discontinued adjuvant nivolumab prematurely due to disease progression or irAEs. These findings highlight the need for careful patient selection and monitoring when using adjuvant immunotherapy in this population.
Ključne besede: oesophageal cancer, gastroesophageal junction cancer, adjuvant immunotherapy, nivolumab
Objavljeno v DiRROS: 18.06.2026; Ogledov: 200; Prenosov: 82
Celotno besedilo (828,77 KB) |
6. |
7. |
8. Elementi v sledovih v serumu kot potencialni biomarkerji pri bolnikih z raki biliarnega trakta : preliminarni rezultatiMartina Reberšek, Nežka Hribernik, Katarina Kozlica, Katja Uršič Valentinuzzi, Maja Čemažar, Radmila Milačič Ščančar, Janez Ščančar, 2025, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: biološki označevalci, raki biliarnega trakta, onkologija
Objavljeno v DiRROS: 11.03.2026; Ogledov: 581; Prenosov: 135
Celotno besedilo (107,87 KB) |
9. |
10. |
